Author Archives: admin


Stem Cell Clinic > Articles by: admin

The Aivee effect

By Stem Cell Clinic

Dr. Aivee Teos newest clinic combines multi-faceted skin typing with essential treatments to get The Aivee Glow

August 28, 2014The Aivee Clinic officially launches at the SM Mega Fashion Hall. After five years since opening her posh clinic at the Fort, Dr. Aivee Teo elevates her passion for advanced skin care technology and anti-aging treatments with the new clinic concept, The Aivee Clinic. The beauty hub couldnt have been in a better locationstationed alongside global fashion brands. Dr. Aivee Teo, one of the countrys most sought after dermatologists, after all, has as much passion for beauty as she has for fashion. Her success in the business of skin care is widely known, and as a fashion lover, she has constantly been on best-dressed lists. Beauty and fashion truly go hand in hand.

What started out as a practice in the pursuit of beauty, one that thrived purely on word of mouth, has inevitably made Dr. Aivee as one of the major players in the industry. Getting healthy, blemish-free, and luminous skin using non-invasive or minimally invasive methods has always been her technique. And she continues to push the standards with a full integration of beauty and wellness with The Aivee Group.

AIVEE LEAGUE

What is The Aivee Glow? Its a signature look defined as a luminous, radiant, and natural beauty that transcends external perfection. With the new clinic, Dr. Aivee strengthens the four pillars of The Aivee Group: The Aivee Institute (first class center for advanced dermatology, cosmetic surgery, hair restoration, and aesthetic stem cell therapy), Stemcare Institute (premiere center for pain and regenerative medicine using fat stem cells), Aivee Skin Science (research center for developing cosmeceutical and nutriceutical products) and now, The Aivee Clinic (skin-focused approach for no-downtime treatments). The Aivee Group is one well-oiled machine, with all its parts complementing each other toward a holistic beauty goal.

GRADE A

Its no secret that the husband and wife partnership of Dr. Z and Aivee Teo, their love and commitment for each other and their field, has brought them happiness and success. From surviving a long-distance relationship, shuffling back and forth Manila and Singapore to attend to their respective clinics, and always pursuing new ways to rejuvenate skin and provide a sense of well-being. All this while keeping their children close by and rarely being separate from each other. And if youve ever had the privilege of interviewing them together, they really finish each others sentences. Whether thats about their practice or about how they commit to make everything work for their family and business.

This dynamic duo established their anti-aging institute over a decade ago, utilizing maintenance procedures, non-invasive lasers, cutting edge technology such as stem cell therapy and liquid face lifts, and cosmetic surgery. The awareness of the growing needs of their patients and their recent travels to the US and Europe brought them to a new realization. With patients requesting for dramatic makeover programs, twice-a-year rejuvenation therapies and innovative treatments with the least amount or no downtime, SmartSkin became the clear answer as the way to move forward.

The SmartSkin Typing concept is a multi-faceted system with a digital tailor-made evaluation of the skin. By assessing and categorizing skin as oily or dry, sensitive or resistant, pigmented or non-pigmented, wrinkled or tight, you come up with a very specific skin type. From this, a highly customized skin treatment can easily be made. In keeping with the holistic approach, skin experts at The Aivee Clinic can then set the appropriate treatment programprocedures, health supplements, and skin careto achieve that healthy glow.

SKIN TECH

Go here to see the original:
The Aivee effect

Feds give Cellerant $47.5M for stem cell treatment that preps for nuclear disaster

By Stem Cell Treatment

Stem cell therapy is one way thegovernments preparing for a nationimpacted by nuclear disaster.

Cellerant Therapeutics has received $47.5 million from the government to develop its treatment for radiation poisoning. If approved, the feds could buy the drug for the Strategic National Stockpile, which is a part of Project Bioshield- a portion of the Bush-era War on Terror that medically readies the nation against chemical, biological, radiological or nuclear attacks.

This is part of a $163.8 million commitment from theBiomedical Advanced Research and Development Authority, or BARDA.

The new dollars will go toward San Carlos, California-based Cellerants Phase 2 trial in patients with acute myeloid leukemia, as well as the preclinical trials to treat radiation poisoning, or Acute Radiation Syndrome.

As it relates toradiation poisoning, Cellerant said its drugCLT-008 is meant to provide hematopoietic support after exposure to ionizing radiation such as from a nuclear or radiological weapon, or from a nuclear accident, it said in a statement.

The privately held company also recently wrapped up early-stage clinical studies in patients with acute myeloid leukemia, as well as in patients that are undergoing an umbilical cord blood transplant. Cellerant found CLT-008, was safely tolerated in 75 patients, it said in a statement. Its Phase 2 is testing for a decrease in risk of febrile neutropenia, and infections stemming from chemo.

CLT-008 is essentially a collection of deep-freezed stem cells that can ultimately defrost and mature into working granulocytes, platelets and red blood cells in a person. In nonclinical models, Cellerant has shown that the treatments highly effective in providing protection from lethal radiation, preventing infection, facilitating stem cell engraftment and improving overall survival.

Get our daily newsletter or follow us.

Please enter your email below:

Originally posted here:
Feds give Cellerant $47.5M for stem cell treatment that preps for nuclear disaster

Community rallies for 12-year-old from Pine Island battling leukemia

By Stem Cell Clinic

PINE ISLAND, Minn. (KTTC) -- A Pine Island sixth grader is preparing to return to school after a nearly year-long battle with leukemia. Lacey McClain, 12, was diagnosed with T-cell acute lymphoblastic leukemia last year and has undergone extensive treatment at Mayo Clinic Hospital, Saint Marys Campus since the diagnosis.

We thought she had mono, said Lacey's mom, Chrissie Jurrens. We took her in to make sure that was the case and the doctor came to us and said her white cell blood count was way higher than normal."

In fact, Lacey's white blood cell count was more than 20 times above normal. On October 29, 2013, she was diagnosed and immediately began aggressive chemotherapy treatment. It wasn't until January that Lacey began going into remission. Her battle didn't end there. Doctors told the family Lacey would also need a stem cell transplant.

Chemotherapy isn't easy on anybody's body, but she did a really good job of keeping her composure and staying strong and just knowing she was going to get through it, said Jurrens.

Months after going into remission, Lacey received a stem cell transplant on June 3. The transplant meant a 49-day stay in the hospital. In total, the 12-year-old has spent more than 100 days in the hospital.

She was my strength and I tried the best I could to be hers," said Jurrens. "We just stuck together."

Since her homecoming in late July, Lacey has spent much of her time resting and keeping up with doctor's appointments in order to get the all clear to go back to school next week. Despite, a compromised immune system, she'll be allowed to return to classes and a normal routine.

I'm excited for her, but I'm nervous because I know that a lot of germs are picked up in school and that's where most kids get sick. I kind of have mixed emotions about it, said Jurrens.

The family hasn't made their journey to recovery alone, Jurrens said there's been an outpouring of support from the community, including a benefit and 5K planned for Saturday, September 13.

She's not totally capable of being that normal kid yet, said Jurrens. I know that she's going to get there and I know that we're going to have good times again and I'm going to see her doing the things that I want to see her doing again."

See the rest here:
Community rallies for 12-year-old from Pine Island battling leukemia

Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond

By Uncategorized

Melbourne, Florida (PRWEB) September 11, 2014

Central Florida board-certified veterinary surgeon, Jeffrey S. Christiansen is proud to announce his partnerships with several Brevard County animal hospitals to bring regenerative veterinary medicine to pets. Dr. Christiansen has been working in the area since January 2006, credentialed to do stem cell therapy on small animals since 2008, and is happy to now offer his expertise through five different locations.

Over the years Dr. Christiansen has used stem cell therapy with Vet-Stem, Inc. on cruciate ligament and meniscus injuries, as well as osteoarthritis of the hips and other joints. Once Dr. Christiansen has identified a patient as a good stem cell therapy candidate, the pet undergoes a simple surgery to collect fat that is sent overnight to Vet-Stems lab in California. The day after the collection the fat is processed so stem cells can be extracted and put into concentrated, injectable doses. These doses are shipped back overnight to Dr. Christiansen and he is able to place them in the affected areas of the patient to encourage healing and regeneration.

Even if a pet is not an immediate candidate for stem cell therapy, but is undergoing an orthopedic or other type of surgery with Dr. Christiansen, he offers the ability to collect a small sample of fat for future stem cell use with Vet-Stem. Vet-Stem has the ability to cryo-bank stem cells and grow them in the future to provide doses when needed. This service is called StemInsure for dogs, and provides the insurance of a pet having a lifetime of stem cell therapy available from a single sample collection.

Stem cell therapy can be an alternative for pets that are unable to take anti-inflammatories or have digestive issues, as well as pets that are looking at long-term pain management. Because the stem cells come directly from the patient risk is low, and the procedure is natural.

As part of Superior Veterinary Surgical (and less-invasive) Solutions, Dr. Christiansen will be offering stem cell therapy at the following clinics beginning in September: Island Animal Hospital in Merritt Island, Brevard Animal Emergency Hospital in Malabar, Aloha Pet and Bird Hospital in Indian Harbour, Maybeck Animal Hospital in West Melbourne, and the Animal Emergency and Referral Center in Fort Pierce. He is bringing nearly 20 years of veterinary medicine experience with him, and takes pride in specializing in soft tissue, orthopedic, and spinal surgery.

About Dr. Christiansen and Superior Veterinary Surgical Solutions Jeffrey S. Christiansen, DVM, DACVS graduated from the University of Tennessee College of Veterinary Medicine in 1996. He completed his surgical residency in 2001, following an internship, and in 2002 he became a Diplomate of the American College of Veterinary Surgeons. Dr. Christiansen has been practicing in Brevard County since the beginning of 2006 and runs Superior Veterinary Surgical Solutions. In addition to stem cell therapy, some special areas of interest to Dr. Christiansen include artificial urethral sphincter (for incontinence), juvenile pubic symphysiodesis (for prevention of arthritis secondary to hip dysplasia), prophylactic gastropexy (for prevention of gastric dilatation-volvulus, commonly referred to as bloat), subcutaneous ureteral bypass (for obstructions between the kidney and bladder in cats), ureteral stenting (for obstruction between the kidney and bladder in dogs), and urethral stenting (for urethral obstruction), tibial tuberosity advancement (for tears of the cranial cruciate ligament; ACL in people) and tracheal stenting (for tracheal collapse).

About Vet-Stem, Inc. Since its formation in 2002, Vet-Stem, Inc. has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem pioneered the use of regenerative stem cells for horses, dogs, cats, and some exotics. In 2004 the first horse was treated with Vet-Stem Regenerative Cell Therapy for a tendon injury that would normally have been career ending. Ten years later Vet-Stem celebrated its 10,000th animal treated, and the success of establishing stem cell therapy as a regenerative medicine for certain inflammatory, degenerative, and arthritic diseases. As animal advocates, veterinarians, veterinary technicians, and cell biologists, the team at Vet-Stem tasks themselves with the responsibility of discovering, refining, and bringing to market innovative medical therapies that utilize the bodys own healing and regenerative cells. For more information about Vet-Stem and Regenerative Veterinary Medicine visit http://www.vet-stem.com or call 858-748-2004.

Continue reading here:
Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond

Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014

By Stem Cell Treatment

San Antonio, TX (PRWEB) September 11, 2014

The Stem Cell Institute, located in Panama City, Panama, will present an informational seminar about umbilical cord stem cell therapy on Saturday, September 20, 2014 in San Antonio, Texas at the La Cantera Hill Country Resort from 1:00 pm to 4:00 pm.

Stem Cell Institute Speakers include:

Neil Riordan PhD Umbilical Cord Stem Cell Clinical Trials for MS and Autism: Rationale and Clinical Protocols

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Umbilical Cord Stem Cell Therapy for Arthritis, Inflammation and Sports Injuries

Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Special Guest Speaker:

Janet Vaughan, DDS, MS, Professional Dancer- Successful Stem Cell Therapy in Panama: A Patients Perspective

Dr. Vaughan is Board Certified in Orthodontics (Diplomate of the American Board of Orthodontics) and she is a Fellow in the International College of Dentistry.

Follow this link:
Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014

Induced Stem Cells Will Be Tested on Humans for the First Time

By Stem Cell Treatment

Back in 2006, when controversy over embryonic stem cell funding was still raging, a piece of research came along that would make the debate essentially obsolete: normal adult cells can actually be reprogrammed into stem cells. No embryos necessary. The technique went on to win its inventor the Nobel Prize. And now, after many years in the lab, a Japanese patient will the first person to receive the next-gen treatment, called induced pluripotent stem cells.

This first clinical trial for iPSCs has long been in the making. Part of its complexity is that cells are taken from each patient and then, through a series of lab procedures, transformed into stem cells. Each patient gets his or her own genetically matched iPSCs.

This individualization is a key advantage over embryonic stem cells, which have been tested in humans before. Special drugs are required to prevent patients' bodies from rejecting embryonic stem cells.

After some final safety checks and genetic tests, the first clinical trial is officially underway in Japan. Nature reports that the first patient will likely receive iPSCs within days. In total, the clinical trial has enrolled six patients, all of whom with an eye condition called macular degeneration that leads to blindness. The iPSCs will replace a deteriorated layer of cells in their retinas.

So far, the procedure has worked without serious adverse effects (usually tumors) in mice and monkeys. If it works in humans, iPSCs could be a promising new avenue for human stem cell therapy, which, if you remember, could hold the key to all sorts of incurable conditions from diabetes to Parkinson's to spinal cord injuries. This is a small first step in that direction. [Nature]

Top image: an eye with signs of macular degeneration. National Eye Institute

Read more from the original source:
Induced Stem Cells Will Be Tested on Humans for the First Time

UCSD Medical School Holding Clinical Trials For Stem Cell …

By Stem Cell Clinic

UC San Diego is initial site for first-in-human testing of implanted cell therapy.

Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc, a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes.

The trial will assess the safety and efficacy of a new investigational drug called VC-01, which was recently approved for testing by the U.S. Food and Drug Administration. The two-year trial will involve four to six testing sites, the first being at UC San Diego, and will recruit approximately 40 study participants.

The goal, first and foremost, of this unprecedented human trial is to evaluate the safety, tolerability and efficacy of various doses of VC-01 among patients with type 1 diabetes mellitus, said principal investigator Robert R. Henry, MD, professor of medicine in the Division of Endocrinology and Metabolism at UC San Diego.

He is also chief of the Section of Endocrinology, Metabolism & Diabetes at the Veterans Affairs San Diego Healthcare System.

We will be implanting specially encapsulated stem cell-derived cells under the skin of patients where its believed they will mature into pancreatic beta cells able to produce a continuous supply of needed insulin.

Previous tests in animals showed promising results. We now need to determine that this approach is safe in people.

Development and testing of VC-01 is funded, in part, by the California Institute for Regenerative Medicine, the states stem cell agency, the UC San Diego Sanford Stem Cell Clinical Center and JDRF, the leading research and advocacy organization funding type 1 diabetes research.

Type 1 diabetes mellitus is a life-threatening chronic condition in which the pancreas produces little or no insulin, a hormone needed to allow glucose to enter cells to produce energy.

It is typically diagnosed during childhood or adolescence, though it can also begin in adults. Though far less common than Type 2 diabetes, which occurs when the body becomes resistant to insulin, Type 1 may affect up to 3 million Americans, according to the JDRF.

See the article here:
UCSD Medical School Holding Clinical Trials For Stem Cell ...

Stem Cell Discovery Important for Regenerative Medicine …

By Uncategorized

A new stem cell discovery might one day lead to a more streamlined process for obtaining stem cells, which in turn could be used in the development of replacement tissue for failing body parts, according to scientists. Building on a strategy that involves reprogramming adult cells back to an embryonic state in which they again have the potential to become any type of cell, University of California/San Francisco (UCSF; California, USA), researchers have genetically removed multiple barriers to reprogramming, finding that the efficiency of generation of induced pluripotent stem (iPS) cells can be greatly increased. Reporting that: Genetic interaction studies of endocytosis or ubiquitination reveal that barrier pathways can act in linear, parallel, or feedforward loop architectures to antagonize reprogramming, the study authors submit that: These results provide a global view of barriers to human cellular reprogramming.

Qin H, Diaz A, Blouin L, Lebbink RJ, Patena W, Tanbun P, LeProust EM, McManus MT, Song JS, Ramalho-Santos M. Systematic Identification of Barriers to Human iPSC Generation. Cell. 2014 Jul 17;158(2):449-61.

Dietary supplementation of resveratrol may enhance memory performance, among older men and women.

University of California team makes discovery about how we obtain stem cells, with potential applications for creating replacement tissues and organs.

Consumed in the diet, capsaicin the active ingredient in chili peppers activates a mechanism that may reduce the risk of colorectal cancer.

Ancestral exposures to the pesticide methoxychlor may lead to adult onset kidney disease, ovarian disease and obesity in future generations.

Literacy in childhood may exert a potent influence on the risk of cognitive impairment later in life.

Type-2 diabetics who consume a diet high in salt may be at twice the risk of developing cardiovascular disease.

Eating baked or broiled fish once a week is good for the brain.

Macadamia nuts along with other tree nuts such as almonds, cashews, and pecans may confer beneficial effects for metabolic parameters of people with type-2

Read this article:
Stem Cell Discovery Important for Regenerative Medicine ...

After FDA Approval, Duchennes Muscular Dystrophy Patient Receives First Umbilical Cord Stem Cell Treatment in the …

By Stem Cell Treatment

Wichita, KS (PRWEB) September 10, 2014

Ryan Benton, a 28 year-old Duchennes muscular dystrophy patient from Wichita, Kansas, received his first umbilical cord tissue-derived mesenchymal stem cell treatment yesterday following US FDA approval of his doctors application for a single patient, investigational new drug (IND) for compassionate use.

Duchenne muscular dystrophy (DMD) is a rapidly progressive form of muscular dystrophy that occurs primarily in boys. It is caused by an alteration (mutation) in a gene, called the DMD gene, which causes the muscles to stop producing the protein dystrophin. Individuals who have DMD experience progressive loss of muscle function and weakness, which begins in the lower limbs and leads to progressively worsening disability. Death usually occurs by age 25, typically from lung disorders. There is no known cure for DMD.

This trial, officially entitled Allogeneic transplantation of human umbilical cord mesenchymal stem cells (UC-MSC) for a single male patient with Duchenne Muscular Dystrophy (DMD) marks the first time the FDA has approved an investigational allogeneic stem cell treatment for Duchennes in the United States.

Ryan received his first intramuscular stem cell injections from allergy and immunology specialist, Van Strickland, M.D at Asthma and Allergy Specialists in Wichita, Kansas. He will receive 3 more treatments this week on consecutive days. Dr. Strickland will administer similar courses to Ryan every 6 months for a total of 3 years.

This is not the first time Ryan has undergone umbilical cord mesenchymal stem cell therapy. Since 2009, Ryan has been traveling to the Stem Cell Institute in Panama for similar treatments. Encouraging results from these treatments prompted Dr. Strickland to seek out a way to treat Ryan in the United States.

The stem cell technology being utilized in this trial was developed by renowned stem cell scientist Neil H. Riordan, PhD. Dr. Riordan is the founder and president of the Stem Cell Institute in Panama City, Panama and Medistem Panama. Medistem Panama is providing cell harvesting and banking services for their US-based cGMP laboratory partner.

Funding for this trial is being provided by the Aidan Foundation, a non-profit organization founded by Dr. Riordan in 2004 to provide financial assistance for alternative therapies to people like Ryan.

About Van Strickland, MD

Dr. Strickland came to Wichita in 1979 from his fellowship at the National Jewish Hospital in Denver. Since then he has spent one year in Wyoming, one year in Dallas, Texas and one year in Lees Summit Missouri before returning to full-time practice in Wichita, Kansas.

More:
After FDA Approval, Duchennes Muscular Dystrophy Patient Receives First Umbilical Cord Stem Cell Treatment in the ...

MS stem-cell breakthrough led by Italians

By Stem Cell Treatment

'So far appears safe, without side effects'

(ANSA) - Boston, September 9 - Mesenchymal stem cell therapy to treat multiple sclerosis so far appears safe and without side effects, according to data released Tuesday and obtained through clinical trials on patients as part of the international Mesems project coordinated by University of Genoa neurologist Antonio Uccelli. The results were announced ahead of the World Congress on Treatment and Research in Multiple Sclerosis opening in Boston Wednesday through Saturday. The Mesems project involves researchers from nine countries - Italy, Spain, France, Britain, Sweden, Denmark, Switzerland, Canada and Australia. It is the first large phase II international multicentre clinical trial to determine the safety of a consensus treatment protocol established by the International Mesenchymal Stem Cells Transplantation Study Group to obtain information on its effectiveness on multiple sclerosis patients. So far, 81 patients have been involved in the project - half of the 160 needed for the whole clinical trial. About 73 - or 90% of those involved in blind testing - were given at least one injection with mesenchymal therapy or got a placebo while 51 - or 63% - were given both injections and 27 - 33% - completed the study. "The promising result is that so far none of these 27 people have suffered significant adverse events, which means that, so far, the treatment appears to be safe", said Uccelli. The neurologist warned that "caution is necessary" and that the effectiveness of the therapy can only be determined once the study is completed in 2016. Uccelli however added that preliminary studies on animals have persuaded researchers that mesenchymal stem cells "can halt inflammation on the central nervous system and probably succeed in protecting nervous tissue, even repairing it where damage is minor". Out of the 81 patients recruited so far, "28 are Italian and 10 of them have completed the study", Uccelli said, adding that all patients over the past year did relatively well except for one who was treated with placebo. The neurologist expressed the hope that "data in 2016 will give final confirmation that the therapy is effective so we can take the subsequent step with a larger phase III study aimed at demonstrating the role of stem cells as neurorepairers". Meanwhile Genoa's bioethics committee has approved a two-year extension of the project, which will be called Mesems Plus, "to verify, beyond the year of observation provided for by Mesems, the long-term safety of treatments in the study and the potential insurgence of adverse events in all those treated", said Uccelli.

Read more:
MS stem-cell breakthrough led by Italians

→←